Could the CEO of Valeant Pharmaceuticals Intl Inc. Be the Next Warren Buffett?

Warren Buffett has grown his empire by buying great companies. The CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing the exact same thing. Could that make him the next Buffett?

| More on:
The Motley Fool

One thing that Warren Buffett does very well is buy businesses. With the amount of capital that he has available to him through Berkshire Hathaway Inc., he can go out and buy out an entire company without blinking an eye.

And then when he does buy these companies, he is able to integrate them into the overall structure, and take the cash flow they provide to make even larger investments. This is how Buffett went from buying stocks—which he still does to an extent—to outright buying businesses.

Believe it or not, J. Michael Pearson, the CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing something quite similar. And Bill Ackman, the hedge fund manager of Pershing Square Capital, believes that Valeant could be this generation’s Berkshire.

Ackman has invested 20% of his funds into Valeant. The reason he believes that he is holding a large stake in the next Berkshire is because of how many acquisitions Valeant makes every year. He views the company as a “platform company,” meaning it buys other companies to increase its own value. Instead of launching organic projects, it just buys them. That sounds a lot like Berkshire to me.

Over the past seven years Valeant has acquired over 100 businesses. And according to Ackman, they’ve been integrated into the larger organization rather seamlessly. If Pearson is good at one thing, it’s finding efficiency when combining companies.

Why this matters to you

Valeant isn’t slowing down. The company is going to continue buying other firms—large and small—with the goal of increasing its size. That’s how Berkshire works and that’s likely how Valeant is going to continue to work over the coming years.

This matters to you because platform companies are perpetually undervalued. Ackman has two examples to back this up. When the company bought Bausch & Lomb, the stock was valued at $74. The announcement of its agreement to buy made the price jump to $95. When it agreed to buy Salix Pharmaceuticals, the stock jumped from $217 to $250.

Now, there’s no denying that this stock has been on a meteoric rise. And Ackman’s belief is that the company will continue to make acquisitions in the $7-20 billion range every year. Pearson is not looking to create just another company; he wants to build a behemoth. And his strategy is to follow in the footsteps of the greatest investor of all time: Warren Buffett.

All of this, however, doesn’t immediately warrant a buy. Valeant is risky. It has a lot of debt and it doesn’t pay a penny in dividends to investors. Therefore, what you’re hoping for is a continuous rise in the price per share. In the event that the market corrects, this stock will drop because all stocks will drop.

But long term, if Pearson is successful and if Ackman can correctly predict the undervaluation of platform companies, then this stock will reward investors handsomely.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

heavy construction machines needed for infrastructure buildout
Stocks for Beginners

Canada’s Infrastructure Boom: 3 TSX Stocks I’d Buy Now

Canada’s infrastructure boom could reward the companies already positioned to turn new projects into real revenue.

Read more »

tsx today
Stock Market

TSX Today: What to Watch for in Stocks on Tuesday, April 28

TSX weakness extended into a third straight session despite strong energy stocks, with today’s direction likely tied to geopolitical developments…

Read more »

hand stacks coins
Dividend Stocks

3 Canadian Stocks That Could Be an Ideal Fit for a $7,000 TFSA Investment

A balanced TFSA portfolio starts with the right stocks -- here are three strong contenders.

Read more »

Real estate investment concept
Dividend Stocks

A Reliable Monthly Dividend Stock With a 4.5% Yield Worth Considering

Morguard North American Residential REIT (TSX:MRG.UN) offers a compelling 4.5% yield as it transforms from high-risk payer to blue-chip contender…

Read more »

man in suit looks at a computer with an anxious expression
Dividend Stocks

If I Could Only Buy and Hold a Single Stock, This Would Be It

Thomson Reuters has quietly doubled its financials since 2019. With AI tailwinds, a fortress balance sheet, and 9% legal growth,…

Read more »

panning for gold uncovers nuggets and flakes
Metals and Mining Stocks

1 Gold and Silver Mining Stock to Buy in April

Gold trades above $3,000 and silver above $90. Two mining stocks stand out right now: Agnico Eagle and Endeavour Silver.…

Read more »

stocks climbing green bull market
Investing

The Canadian Stocks I’d Consider If I Had $5,000 to Invest in 2026

In today’s volatile market, investors can balance risks and returns with a balanced portfolio of growth, defensive, and dividend-paying stocks.

Read more »

man crosses arms and hands to make stop sign
Dividend Stocks

The Dividend Stock I Own and Have Zero Intention of Ever Selling

Here's why this dividend stock isn't just one of the best to buy on the TSX, but one you'll never…

Read more »